Up to $1.2 trillion in productivity across sales and marketing is the figure Terret is staking to Nexus, a new AI-native revenue platform the Santa Clara, Calif., company announced July 15 via PRNewswire. Terret describes Nexus as the first platform to autonomously diagnose and fix broken sales pipelines, converting revenue insights into automated execution for enterprise go-to-market teams.
The $1.2 trillion figure
The "up to" qualifier is the critical term. Terret is presenting $1.2 trillion as a ceiling on potential productivity gains across enterprise sales and marketing functions, not a contracted, realized, or independently verified outcome. The company has not disclosed in the available announcement text what data or methodology supports that ceiling.
The scale of the claim frames Nexus as enterprise-category infrastructure rather than a departmental tool. Terret is arguing that the value currently lost in broken sales pipelines is measurable at the trillion-dollar level. That argument implies a large addressable market for a platform positioned as the autonomous execution layer sitting above existing sales data.
No pricing, customer count, partnership, or run-rate data were included in the announcement. Terret's own revenue figures are not disclosed.
The "first" claim
Terret is calling Nexus the first revenue platform to autonomously diagnose and fix broken pipelines. That "first" carries competitive weight. It implies no comparable platform currently handles both diagnosis and automated remediation inside a single workflow.
The Nexus name suggests a connecting architecture, one that bridges the gap between revenue data and the actions sales teams must take on it. Terret describes itself as AI-native, positioning automation as the core product function rather than an added intelligence layer.
What the release leaves open
The announcement does not include a general availability date, named enterprise customers, or the specific pipeline failure modes Nexus is designed to address. What the system automates versus what returns to a human is not specified. Investors and operators evaluating the $1.2 trillion claim will need additional disclosures, including methodology, before the figure can be stress-tested against Terret's actual commercial pipeline.